Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Earnings

MDGL Earnings Reports

Positive Surprise Ratio

MDGL beat 24 of 43 last estimates.

56%

Next Report

Next Week

Date of Next Report

Nov 03, 2026

Estimate for Q3 26 (Revenue/ EPS)

$412.35M

-$0.89

Implied change from Q2 26 (Revenue/ EPS)

+13.20%

-55.28%

Implied change from Q3 25 (Revenue/ EPS)

+43.54%

-82.06%

Madrigal Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On Jul 30, 2026, MDGL reported earnings of -1.99 USD per share (EPS) for Q2 26, beating the estimate of -2.61 USD, resulting in a 23.96% surprise. Revenue reached 364.25 million, compared to an expected 360.24 million, with a 1.11% difference. The market reacted with a -9.83% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 12 analysts forecast an EPS of -0.89 USD, with revenue projected to reach 412.35 million USD, implying an decrease of -55.28% EPS, and increase of 13.20% in Revenue from the last quarter.

FAQ

What were Madrigal Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Madrigal Pharmaceuticals, Inc. Common Stock reported EPS of -$1.99, beating estimates by 23.96%, and revenue of $364.25M, 1.11% above expectations.

How did the market react to Madrigal Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -9.83%, changed from $546.88 before the earnings release to $493.11 the day after.

When is Madrigal Pharmaceuticals, Inc. Common Stock expected to report next?

The next earning report is scheduled for Nov 03, 2026.

What are the forecasts for Madrigal Pharmaceuticals, Inc. Common Stock's next earnings report?

Based on 12 analysts, Madrigal Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.89 and revenue of $412.35M for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.